Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
Managed Care August 2006 Martin Sipkoff	Off-Label Use Often Presents Conundrum for Health Plans Insurers recognize the clinical importance of off-label prescribing, but criteria are needed to avoid over-utilization.
BusinessWeek July 2, 2007 Arlene Weintraub	Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound.
Wired September 25, 2007 Patrick Di Justo	From Benzedrine to Abilify, Chronicling America's Love of Psychiatric Drugs A history of what Americans have used to battle depression.
Salon.com March 9, 2000 Lawrence H. Diller, M.D.	Kids on drugs A behavioral pediatrician questions the wisdom of medicating our children.
The Motley Fool December 22, 2006 Stephen Albainy-Jenei	Is Off-Label Off-Base? Off-label prescriptions for uses lacking scientific support account for billions in drug revenue for Eli Lilly. If the FDA takes an aggressive stance on off-label-use marketing, it could significantly shrink drug sales for companies whose revenues are derived largely from such off-label use.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool December 3, 2010 Travis Hoium	Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement.
Chemistry World July 18, 2012 Andrew Turley	Obesity drug approved in US US regulators have approved a new obesity treatment. Qsymia (phentermine, topiramate) tablets have been approved for overweight adults as part of a regimen that includes a low calorie diet and exercise.
The Motley Fool April 7, 2011 Brian Orelli	Restless No Longer XenoPort and Glaxo get a delayed FDA approval.
The Motley Fool June 11, 2009 Brian Orelli	Kids, Take Your Antipsychotics! Drugs to combat mental illness might gain FDA approval for children.
The Motley Fool March 31, 2011 Brian Orelli	Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good.
The Motley Fool November 5, 2010 Brian Orelli	Better Late Than Never for Cymbalta Eli Lilly gets an expanded approval for Cymbalta.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
Managed Care November 1999	N.J. Regulators Take Hard Look At Diet-Pill Mills New Jersey would become the fourth state to enact regulations governing distribution of weight-loss drugs, if a state Board of Medical Examiners proposal is approved....
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool January 12, 2010 Dayana Yochim	6 Ways to Score Cheap(er) Drugs Stop overpaying for the pills you have to pop with these simple ways to trim your prescription-drug tab.
ifeminists May 24, 2006 Gerald K. McOscar	ADHD Is it child abuse per se for parents to allow doctors to prescribe mind altering drugs with potentially serious or fatal psychiatric side effects to their children, no matter how challenged...or challenging?
Health September 2007 Jennifer Acosta Scott	Can Medicine Make You Fat? In a word, yes. Here's what to do when the drugs you need also put on the pounds.
The Motley Fool December 4, 2007 Brian Orelli	An Early Gift to Drugmakers Drugmakers could be allowed to market for drugs' off-label indications.
The Motley Fool January 25, 2011 Brian Orelli	FDA Approved -- Now Will It Sell? There's still plenty of uncertainty in Clinical Data's shares.
Salon.com May 23, 2002 Lawrence H. Diller	A prescription for disaster The failure to test the effects in children of routinely prescribed drugs has resulted in at least one death. How many kids will die before drug companies take steps to ensure their safety?
Health September 2007	Are Drugs Sabotaging Your Diet? Anybody who gains five pounds in a month of taking a new medication should see their doctor immediately.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
The Motley Fool June 25, 2010 Brian Orelli	Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review.
The Motley Fool January 31, 2011 Brian Orelli	Drug Approved! Now Who's Going to Launch It? Depomed gets pain-free news from the FDA.
The Motley Fool September 16, 2010 Brian Orelli	Abbott's Product Line May Get Thinner Not that it needs the obesity drug.
Reason April 2008 Ronald Bailey	Medical Speech As a 1997 law expires, the FDA is mulling a plan allowing companies to disseminate unabridged reprints of "truthful and non-misleading" medical journal articles describing "off-label" uses of approved medications to physicians.
BusinessWeek December 22, 2003 Howard Gleckman	Seniors' Big Drug Problem Misusing medications is a leading cause of death among the elderly.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
AskMen.com James Fell	Qnexa Do the substantial weight-loss benefits of Qnexa more than compensate for the risks of taking it?
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
BusinessWeek October 18, 2004 John Carey	"Off-Label" -- And Out Of Bounds? When drugmakers promote products for unproven uses, they may be courting trouble. How restrictive should the regulations be?
The Motley Fool November 22, 2006 Brian Lawler	How to Market a Drug Too Well Cephalon's promotion of its pain drug Actiq might have crossed the line.
BusinessWeek March 11, 2010 Margaret Cronin Fisk et al.	Did J&J Plan to Break Rules? Its aggressive marketing campaign for Risperdal has caused an explosion of litigation.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
The Motley Fool September 28, 2010 Brian Orelli	Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs.
Chemistry World June 6, 2013 Phillip Broadwith	Big data to sniff out drug marketing fraud The US Food and Drug Administration is offering a contract for a company to collect and analyze data on pharma companies' promotional activities. The aim is to use this big data approach to spot off-label marketing and other forms of marketing fraud.
The Motley Fool January 27, 2009 Robert Steyer	Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?
The Motley Fool October 2, 2007 Billy Fisher	Closure for Bristol-Myers Bristol-Myers will pay $515 million to resolve cases from state and federal authorities alleging that the company promoted products for uses that hadn't been approved by the FDA.
BusinessWeek April 26, 2004 Carol Marie Cropper	A Cloud Over Antidepressants Do some popular drugs cause suicidal behavior in teens?
Managed Care December 2004 Jack McCain	The Weight Debate, Continued This article presents the views of people who indulge in what many regard as health care heresy. They challenge the conventional wisdom that millions of Americans need to lose tons of weight, fast, to stave off diabetes, heart disease, cancer.
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
AskMen.com Dustin Driver	Extreme Weight Loss Techniques Nine techniques to lose weight fast, but be warned that there are risks involved with losing weight too quickly.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
Chemistry World November 11, 2013 Sarah Houlton	Mis-selling lands J&J with $2.2bn fine Johnson & Johnson has been given a hefty fine in the US for mis-selling three drugs. The company, and its subsidiaries Janssen and Scios, will pay $2.2 billion.
Managed Care August 2005	Dispensing Machine Promotes Use of Generic Medications Generic drugs are being dispensed in doctors' offices by devices that function much like automatic teller machines that banks use, under a program sponsored by Blue Cross Blue Shield of North Dakota.
The Motley Fool February 18, 2010 Brian Orelli	Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance.
The Motley Fool August 24, 2007 Brian Orelli	Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note.
Reason September 2005 Kerry Howley	Locking Up Life-Saving Drugs U.S. prescription laws make us sicker and poorer because the system that puts drugs over the counter is driven by profits and patents.